2023 World Conference on Lung Cancer (Posters)-EP12.01. Combination of Osimertinib plus Capmatinib in a Patient with EGFR-mutant, T790M positive and MET amplification: A Case Report

EP12.01. Combination of Osimertinib plus Capmatinib in a Patient with EGFR-mutant, T790M positive and MET amplification: A Case Report - PDF(Abstract)

Back to course

Pdf Summary

This case report discusses a patient with advanced stage non-small cell lung cancer (NSCLC) who had a mutation in the epidermal growth factor receptor (EGFR) gene, specifically the T790M mutation. The patient also had MET amplification, which is associated with resistance to EGFR inhibitors and poorer outcomes. The standard treatment for NSCLC patients with the T790M mutation is osimertinib, however, in this case, the combination of osimertinib and capmatinib was used as a late-line treatment.<br /><br />The patient, a 70-year-old woman, initially presented with chronic cough and bone pain. Imaging scans revealed a 5.9 cm lung mass with metastases to the liver and bones. She received erlotinib as frontline treatment, which resulted in a partial response. However, after 21 months, the disease progressed, and the T790M mutation was detected. Osimertinib was then given as second-line treatment, resulting in stable disease for a period of time. However, the patient developed dyspnea and further testing revealed the presence of MET amplification. In August 2022, the patient started a combination of osimertinib and capmatinib as third-line treatment. The patient experienced fatigue and bilateral leg edema, but ultimately achieved stable disease. However, due to a decline in performance status, the patient decided to discontinue further treatment and pursue best supportive care.<br /><br />The case report highlights the use of the combination of osimertinib and capmatinib in a patient with NSCLC, EGFR mutation, T790M positivity, and MET amplification. The efficacy of this combination therapy was different from previous reports, which focused on patients who were T790M negative and MET-amplified. The marginal effect observed in this subgroup of patients is emphasized.<br /><br />Overall, this case report adds to the understanding of targeted therapy for metastatic NSCLC, specifically in patients with co-alterations in the EGFR and MET pathways.

Asset Subtitle

Kijjakom Thanasombunsukh

Meta Tag

Speaker Kijjakom Thanasombunsukh

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

non-small cell lung cancer

NSCLC

epidermal growth factor receptor

EGFR gene

T790M mutation

MET amplification

osimertinib

capmatinib

combination therapy

targeted therapy